- Home
- PPLI vs ZLAB Comparison
PPLI vs ZLAB Comparison
Compare PPLI & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PPLI | ZLAB |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.6B |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | PPLI | ZLAB |
|---|---|---|
| Price | $43.99 | $24.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 12 |
| Target Price | ★ $50.27 | $34.13 |
| AVG Volume (30 Days) | ★ 1.2M | 1.1M |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.97 | 38.46 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,365,235,000.00 | $460,156,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.45 | $22.41 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 15.33 |
| 52 Week Low | $34.79 | $15.96 |
| 52 Week High | $48.32 | $29.02 |
Technical Indicators
Market Signals| Indicator | PPLI | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 66.77 | 50.60 |
| Support Level | $37.56 | $24.24 |
| Resistance Level | $47.96 | $26.64 |
| Average True Range (ATR) | 1.73 | 1.29 |
| MACD | 0.67 | 0.35 |
| Stochastic Oscillator | 97.70 | 40.61 |
Price Performance
Historical ComparisonAbout PPLI People Incorporated Common Stock
People Inc is a media and publishing business that operates a portfolio of brands, including PEOPLE, Food & Wine, Travel + Leisure, InStyle, Better Homes & Gardens, and Southern Living. The company also holds a minority equity stake in MGM Resorts International.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.